EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Efficacy of intravenous immunoglobulin following plasma exchange in the management of ABO haemolytic disease of the newborn

Yahong Hu, Jing Nie iD

Vox Sanguinis · 2026-07 · 121 (7) · 1032-1040

DOI: 10.1111/vox.70265 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Vox Sanguinis, online erschienen am 12.04.2026. Verfasst von Yahong Hu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Laboratory Science, The First Affiliated Hospital of Xi'an Jiaotong University East Campus, Xi'an, Shaanxi, China. Hauptthemen laut MEDLINE: Immunoglobulins, Intravenous, ABO Blood-Group System, Plasma Exchange, Erythroblastosis, Fetal. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives To evaluate the efficacy of intravenous immunoglobulin (IVIG) after plasma exchange (PE) in neonates with ABO haemolytic disease of the newborn (ABO‐HDN) by assessing serum biomarkers, neurodevelopment and quality of life. Materials and Methods A total of 162 neonates with ABO‐HDN were randomly assigned to four groups: Control ( n = 39), IVIG ( n = 42), PE ( n = 41) and IVIG + PE ( n = 40). Serum markers, Neonatal Behavioural Neurological Assessment (NBNA), Echelle Douleur Inconfort Nouveau‐Ne and Paediatric Quality of Life Inventory (PedsQL4.0) scores were evaluated.

Results

The IVIG + PE group showed the most significant improvement in prealbumin (PA), total bile acid (TBA), total bilirubin (TBIL), procalcitonin (PCT), high‐sensitivity C reactive protein (hs‐CRP) and antibody titre levels ( p < 0.05). Neurodevelopment, comfort and quality of life were significantly enhanced, with reduced jaundice duration and hospitalization time. Adverse event rates were lower in all treatment groups than in the control group ( p < 0.05).

Conclusion

IVIG following PE improves serum biomarkers, antibody titre levels, neurodevelopment and quality of life in ABO‐HDN, supporting its clinical application.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunoglobulins, IntravenousABO Blood-Group SystemPlasma ExchangeErythroblastosis, FetalHumansInfant, NewbornFemaleMaleQuality of LifeBiomarkers

Stichwörter der Autor:innen

ABO haemolytic diseaseintravenous immunoglobulinnewbornplasma exchange

Substanzen

Immunoglobulins, IntravenousABO Blood-Group SystemBiomarkers

Autor:innen und Institutionen

  • Department of Medical Laboratory Science, The First Affiliated Hospital of Xi'an Jiaotong University East Campus, Xi'an, Shaanxi, China.
  • 989 Hospital of the Joint Logistic Support Force of the Chinese People's Liberation Army, Luoyang, China.

ORCID-Profile: Jing Nie

Zitieren

APA

Hu, Y., & Nie, J. (2026). Efficacy of intravenous immunoglobulin following plasma exchange in the management of ABO haemolytic disease of the newborn. Vox Sanguinis, 121(7), 1032-1040. https://doi.org/10.1111/vox.70265

Vancouver

Hu Y, Nie J. Efficacy of intravenous immunoglobulin following plasma exchange in the management of ABO haemolytic disease of the newborn. Vox Sanguinis. 2026;121(7):1032-1040. doi:10.1111/vox.70265

BibTeX
@article{Hu2026,
  author = {Hu, Yahong and Nie, Jing},
  title = {Efficacy of intravenous immunoglobulin following plasma exchange in the management of ABO haemolytic disease of the newborn},
  journal = {Vox Sanguinis},
  year = {2026},
  volume = {121},
  number = {7},
  pages = {1032--1040},
  doi = {10.1111/vox.70265}
}
Kostenlos starten →